Background Vitamin K antagonists are highly effective in preventing stroke in patients with
atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa inhibitor …

Background Management of acute coronary syndromes (ACS) should be guided by an
estimate of patient risk. Objective To develop a simple model to assess the risk for in-hospital …

1.1. Methodology and Evidence Review The recommendations listed in this document are,
whenever possible, evidence based. The current document constitutes a full revision and …

The clinical trial is “the most definitive tool for evaluation of the applicability of clinical research.”
It represents “a key research activity with the potential to improve the quality of health …

Background Half of patients with chronic heart failure (CHF) have preserved left-ventricular
ejection fraction (LVEF), but few treatments have specifically been assessed in such patients. …

The recommendations listed in this clinical practice guideline are, whenever possible,
evidence-based. An initial extensive evidence review, which included literature derived from …

Background Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration
of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly …

Background Angiotensin-converting-enzyme (ACE) inhibitors improve outcome of patients
with chronic heart failure (CHF). A substantial proportion of patients, however, experience no …

The scope of this focused update is limited to addressing recommendations on duration of
dual antiplatelet therapy (DAPT)(aspirin plus a P2Y12 inhibitor) in patients with coronary …

Background Angiotensin II type 1 receptor blockers have favourable effects on haemodynamic
measurements, neurohumoral activity, and left-ventricular remodelling when added to …